@Article{096504016X14570992647041,
AUTHOR = {Huijie Jia, Tiesuo Zhao, Di Zou, Xiaolong Jia, Ji Gao, Xiangfeng Song},
TITLE = {Therapeutic Injection of a C-Type CpG ODN Induced an Antitumor  Immune Response in C57/BL6 Mice of Orthotopically Transplanted  Hepatocellular Carcinoma},
JOURNAL = {Oncology Research},
VOLUME = {23},
YEAR = {2015},
NUMBER = {6},
PAGES = {321--326},
URL = {http://www.techscience.com/or/v23n6/57544},
ISSN = {1555-3906},
ABSTRACT = {Synthetic CpG oligodeoxynucleotides (ODNs), as TLR9 agonists, have been found to play a possible role in 
antitumor effect. In order to determine the effect of YW002, known as a C-type CpG ODN, on the treatment of 
hepatocellular carcinoma (HCC), which is one of the most aggressive carcinomas, we chose to inject YW002 at 
the doses of 12.5 μg and 25 μg per mouse 7 days post-tumor challenge. The survival rate of mice was recorded 
every day. On day 14 postinjection, five mice in each group were bled and randomly sacrificed. The level of 
IFN-γ or TNF-α in the serum was detected and lymphocyte infiltration in the tumor tissue; the ratios of CD8+
T cells and CD4+
 T cells in the spleen of mice were also analyzed. The results indicated that treatment with 
YW002 could raise the survival rate and delay tumor growth in the mice with orthotopically transplanted HCC. 
Furthermore, the treatment improved the antitumor immune response through increasing the T-cell infiltration 
in tumor and the ratio of CD4+
, CD8+
, and NK cells in the spleen. In addition, the concentration of IFN-γ was 
raised, and the level of TGF-β was depressed. Our data suggested that CpG ODN might be a proper medicament in a monotherapeutic regimen for treatment of HCC.},
DOI = {10.3727/096504016X14570992647041}
}